Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner

Basit Öğe Kaydı
dc.authoridYAGMURCA, MURAT/0000-0001-9774-8151
dc.authoridgergerlioglu, hasan serdar/0000-0002-8836-0726
dc.authoridOZYURT, Huseyin/0000-0003-2327-4082
dc.authoridGergerlioglu, Hasan Serdar/0000-0002-8836-0726;
dc.authorwosidYAGMURCA, MURAT/A-1851-2018
dc.authorwosidgergerlioglu, hasan serdar/AAG-8348-2021
dc.authorwosidOZYURT, Huseyin/N-4351-2015
dc.authorwosidGergerlioglu, Hasan Serdar/GYQ-5617-2022
dc.authorwosidYAĞMURCA, Murat/AAH-4496-2019
dc.contributor.authorÖzyurt, H
dc.contributor.authorYildirim, Z
dc.contributor.authorKotuk, M
dc.contributor.authorYilmaz, HR
dc.contributor.authorYagmurca, M
dc.contributor.authorIraz, M
dc.contributor.authorSögüt, S
dc.date.accessioned2024-08-04T20:30:50Z
dc.date.available2024-08-04T20:30:50Z
dc.date.issued2004
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe aim of this study was to investigate the optimum dosage of erdosteine to ameliorate cisplatin-induced nephrotoxicity. Three different doses of erdosteine at 25, 50 and 75 mg kg(-1) were studied in rats. Intraperitoneal administration of 7 mg kg(-1) cisplatin led to acute renal failure, as indicated by kidney histology and increases in plasma creatinine and blood urea nitrogen (BUN) levels. At 5 days after cisplatin injection the BUN level was increased significantly from 15.1 +/- 4.3 to 126.7 +/- 152.6 mg dl(-1) and plasma creatinine levels increased from 0.37 +/- 0.005 to 1.68 +/- 1.9 mg dl(-1). When the rats were administered 50 and 75 mg kg(-1) erdosteine 24 h before cisplatin injection that was continued until sacrifice (total of 6 days), the BUN and creatinine levels remained similar to control levels and the grade of histology was similar. Erdosteine at doses of 50 and 75 mg kg(-1) ameliorates cisplatin-induced renal failure. The optimum dose of erdosteine may be 50 mg kg(-1) in this study. Copyright 2004 John Wiley Sons, Ltd.en_US
dc.identifier.doi10.1002/jat.983
dc.identifier.endpage275en_US
dc.identifier.issn0260-437X
dc.identifier.issn1099-1263
dc.identifier.issue4en_US
dc.identifier.pmid15300714en_US
dc.identifier.scopus2-s2.0-4444225768en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage269en_US
dc.identifier.urihttps://doi.org/10.1002/jat.983
dc.identifier.urihttps://hdl.handle.net/11616/94558
dc.identifier.volume24en_US
dc.identifier.wosWOS:000223297700003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Applied Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcisplatinen_US
dc.subjectrenal failureen_US
dc.subjecterdosteineen_US
dc.titleCisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manneren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu